Interestingly, recent studies have identified the role of biologically active NK-EV miRNAs, such as miR-186, which impaired neuroblastoma tumour growth and inhibited immune escape mechanisms by targeting the TGF-β pathway (Neviani et al., 2019); or miR-3607-3p, which inhibited pancreatic cancer, presumably by targeting its putative target IL-26 (Sun et al., 2019). The gene discussed is TGFB1; the disease is neuroblastoma.